1

1. Alfredo AM, Jose FH, Edmundo L, Adriana CP, Marcela L, Role of Innate Immunity against Human
Papillomavirus (HPV) Infections and Effect of Adjuvants in Promoting Specific Immune Response. Viruses
2013;5:2624-42.
2. Loane D, Veronique R, Martine B, Blaise C, Pedro R, Denise NH. Induction of human papillomavirus
oncogene-specific CD8 T-cell effector responses in the genital mucosa of vaccinated mice. Int. J. Cancer.
2010;126:2469–78.
3. Haie CM, Morice P, Castiglione M. Cervical cancer: ESMO Clinical Practice Guidelines for diagnosis,
treatment and follow-up. Annals of Oncology. 2010;21(5): v37–v40.
4. Ankita SR, Sandeep K, Rituraj K, Annu M, Negi MP, Madhu MG. CD3+, CD4+ & CD8+ tumour infiltrating
lymphocytes (TILs) are predictors of favourable survival outcome in infiltrating ductal carcinoma of breast.
Indian J Med Res. 2014;140:361-9.
5. Woo YL, Sterling J, Damay L, Coleman N, Crawford R, Van der Burg SH, Stanley M. Characterising the
local immune responses in cervical intraepithelial neoplasia: a cross- sectional and longitudinal analysis.
BJOG. 2008;115:1616–22.
6. Roth S. Das Zervixkarzinom. In: Roth SL, Boettcher HD, editors. Gyna¨kologische Strahlentherapie.
Stuttgart: Enke Verlag. 1993:14–38.
7. Hanks GE, Herring DF, Kramer S. Patterns of care outcome studies: results of the national practice in cancer
of the cervix. Cancer. 1983;51:959–67.
8. Heilmann HP, Bu¨nemann H. Tumoren der Cervix uteri. In: Scherer E, editor. Strahlentherapie. Berlin:
Springer Verlag. 1987:783–809.
9. Ladner HA. Strahlentherapie des Zervixkarzinoms. In: Teufel G, Pfleiderer A, editors. Therapie des
Zervixkarzinoms. Berlin: Springer Verlag. 1990:241–55.
10. Grigsby PW, Perez CA, Kuske RR, Camel HM, Kao MS, Galakatos AE, et al. Adenocarcinoma of the uterine
cervix: lack of evidence for a poor prognosis. Radiother Oncol. 1988;12:289–96.
11. Horiot JC, Pigneux J, Pourquier H, Schraub S, Achille E, Keiling R, et al. Radiotherapy alo ne in carcinoma
of the intact uterine cervix according to G.H. Fletcher guidelines: a French cooperative study of 1383 cases.
Int J Radiat OncolBiol Phys. 1988;14:605–11
12. FIGO committee on Gynecologic Oncology. Revised FIGO staging for carcinomaof the vulva, cervix and
endometrium. Int J Gynecol Obstet. 2009; 105:103–104.
13. Susworo R. Radioterapi. Dasar-Dasar Radioterapi, Tatalaksana Radioterapi Penyakit Kanker. Universitas
Indonesia. 2007
14. Bermudez RS, Huang K, Hsu IC. Ch 29: Cervical Cancer. Handbook of Evidence beased Radiation
Oncology.
15. Eisenhauer EA, Thwrasse P, Bogaerts J, et al. New response evaluation criteria in solid tumors: Revised
RECIST guideline. European journal of cancer. 2009.
16. Lacombe JA, Del Priore G, Hillier J. Cervical cancer. In: Richard SJ, Del Priore G, Healy J, editors. Atlas of
staging in gynecological cancer. London: Springer-Verlag Ltd. 2008.
17. Hasan A, Rauf S, Malinta U. Penilaian efek kemoterapi kombinasi platinum, vincristin, bleomisin dan
mitomisin C pada karsinoma serviks berdasarkan gambaran apoptosis. Indones J Obstet Gynecol.
2012;36(4):200-5.
18. Katsumata N, Yoshikawa H, Kobayashi H, et al. Phase III randomised controlled trial of neoadjuvant
chemotherapy plus radical surgery vs radical surgery alone for stages IB2, IIA2, and IIB cervical cancer: a
Japan Clinical Oncology Group trial (JCOG 0102). British J of Cancer. 2013;108:1957-63.
19. Richard SJ, Deborah CM, Giuseppe DP. Radical abdominal hysterectomy. In: Richard SJ, Giuseppe DP,
Curtin J, editors. An atlas of gynecologic oncology investigation and surgery. London: Martin Dunitz Ltd;
2001
20. Mario ML, Carol LB. Radical abdominal hysterectomy. In: Douglas AL, Richard RB, Nadeem AR, editors.
Atlas of procedures in gynecologic oncology. 2nd ed. UK: Informa Healthcare. 2008.
21. Dwipoyono B, Nasdaldy, Soemanadi, Sjamsuddin S, Adisasmita AC. Jenis histologik dan umur pada kanker
serviks uteri di rumah sakit kanker “Dharmais”. Indonesia J of Cancer. 2007;1:7-11
22. Amador MA, Fernando HV, Edmundo L, Adriana CP, Marcela L. Role of Innate Immunity against Human
Papillomavirus (HPV) Infections and Effect of Adjuvants in Promoting Specific Immune Response. Viruses.
2013;5:2624-42.
23. American College of Obstetricians and Gynecologists. Human papillomavirus vaccination. ACOG
committee opinion No. 467. Obstet Gynecol. 2010;116:800–803.
24. Edit A, Sylvie V. Human Papillomavirus (HPV) Infection. Institut national de santé publique du Québec.
2005
25. Daniel TG, Juana LS. Human Papillomavirus Infection and Cervical Cancer: Pathogenesis and
Epidemiology. Communicating Current Research and Educational Topics and Trends in Applied
Microbiology. FORMATEX 2007
 2

26. Maria AG, Eduardo AD. Immune Cellular Response to HPV: Current Concepts. BJID. 2004;8(1):1-9
27. Gunasegaran K, Mark LB, Nico VR, Cornelio JD, Jianhe C. Different Roles for CD4+ and CD8+ T
Lymphocytes and Macrophage Subsets in the Control of a Generalized Virus Infection. Journal of Virology.
1996:8301–9
28. Luis ER, Gail RW, Paulette B, Eva F, Jorge EG, Khaled T, Edgardo S, Eckhard RP. CD8 T cell response
in a phase I study of therapeutic vaccination of advanced NSCLC with allogeneic tumor cells secreting
endoplasmic reticulum-chaperone gp96-Ig-peptide complexes. Advances in Lung Cancer. 2013;(2):9-18.
29. Mark JD, Joyce BR, James CH. Kathleen A. CD8-Mediated Type 1 Antitumor Responses Selectively
Modulate Endogenous Differentiated and Nondifferentiated T Cell Localization, Activation, and Function in
Progressive Breast Cancer. Journal of Immunology. 2006;177:8191–201.
30. Anonim. Defining Cancer". National Cancer Institute. Retrieved 10 June 2017.
31. Gao G, Jakobsen B. "Molecular interactions of coreceptor CD8 and MHC class I: the molecular basis for
functional coordination with the T-cell receptor". Immunol Today 21 (12): 630
32. Diananda, R. Kanker Serviks: Sebuah Peringatan Buat Wanita. In: Diananda, R. Mengenal Seluk-Beluk
Kanker. Yogyakarta: Katahari, 2009; 43-60.
33. Kim YT, Kim SW, Yoon BS, Cho HJ, Nahm EJ, et al. Effect of intravenously admiCINtreted iron sucrose
on the prevention of anemia in the cervical cancer patients treated with concurrent chemoradiotherapy. South
Korea : Yonsei University College of Medicine. 2006
34. Suryapratama, Satya Ariza dan M.Besari Adi Pramono. 2010. Karakteristik penderita kanker serviks di RSUP
Dr. Kariadi Semarang Tahun 2010. Jurnal Media Medika Muda.2012
35. Lasut E, Rarung M, Suparman E. Karakteristik Penderita Kanker Serviks di BLU RSUP Prof. Dr. D. Kandou.
Jurnal e-Clinic (eCl), Vol 3 (1), Januari-April 2015
36. Melva. Faktor-Faktor yang Mempengaruhi Kejadian Kanker Leher Rahim Pada Penderita yang Datang
Berobat di RSUP H. Adam Malik Medan. 2008.
37. Bustan, M.N. 2007. Epidemiologi Penyakit Tidak Menular. Jakarta: Rineka Cipta.
38. Nikolich-Zugich J, Li G, Uhrlaub JL, Renkema KR, Smithey MJ. Age-Related Changes in CD8 T Cell
Homeostasis and Immunity to Infection. Seminars in immunology. 2012;24(5):356-364.
39. Womack J, Tien PC, Feldman J, et al. Obesity and Immune Cell Counts in Women. Metabolism: clinical and
experimental. 2007;56(7):998-1004. doi:10.1016/j.metabol.2007.03.008.
40. Reid MJA, Baxi SM, Sheira LA, Landay AL, Frongillo EA, Adedimeji A, et al. Womenʼs Interagency HIV
Study (WIHS). Higher Body Mass Index Is Associated With Greater Proportions of Effector CD8+ T Cells
Expressing CD57 in Women Living With HIV. J Acquir Immune Defic Syndr. 2017 Aug 15;75(5):e132-
e141
41. Gonzalez AD, Graniel CL, Enciso AG, et al. A phase II study of multimodality treatment for locally advanced
cervical cancer: neoadjuvant carboplatin and paclitaxel followed by radical hysterectomy and adjuvant
cisplatin chemoradiation. Annals of Oncol. 2003; 14: 1278–128.
42. Fan JT, Liao Y, Si XH, Geng XL, Wei W, Xie QL. Expression of HLA-I, CD8, and CD4 and Their Clinical
Significance in Cervical Cancer. World Journal of Oncology. 2011;2(1):10-15.
43. Carvalho MO, Nicol AF, Oliveira NS, Cunha CB, Amaro-Filho SM, Russomano FB, et al. Correlation of
CD8 infiltration and expression of its checkpoint proteins PD-L1 and PD-L2 with the stage of cervical
carcinoma. Int J Clin Exp Pathol. 2016;9(10):10406-10413
44. Enwere EK, Kornaga EN, Dean M, Koulis TA, Phan T, Kalantarian M, et al. Expression of PD-L1 and
presence of CD8-positive T cells in pre-treatment specimens of locally advanced cervical cancer. Modern
Pathology. 2017;30:577–86.